Arthritis

There are many forms arthritis, the most common being degenerative osteoarthritis. Some facts excerpted from The World Health Organization literature indicate a number of shocking realities.*

  • Arthritis is considered to be the nation’s number one crippling disease and the most common chronic disease of people over the age of 40.
  • According to the Center for Disease Control and Prevention, an estimated 46 million adults in the United States have been told by a physician that they have some form of arthritis, including degenerative osteoarthritis, rheumatoid arthritis, gout, lupus or psoriatic arthritis.
  • By 2030, a startling 67 million Americans age 18 years or older are projected to have arthritis—a 45% increase from current statistics.
  • The average age that arthritis begins is 47 years, with 1 in 2 Americans over age 65 dealing with some form of arthritis.
  • The cost of arthritis due to lost wages, medical treatment and other related expenses can run an individual over $150,000 in expenses over their lifetime.

These facts are significant–the solutions less so. Physicians are prone to prescribing analgesics, anti-inflammatory medications and muscle relaxants or inject cortisone, xylocaine and a variety of lubricating solutions. All of these mask symptoms temporarily, however they do not provide a permanent solution.

Laser Therapy, a relatively new technology perfected by Meditech International Inc. in Toronto, Canada currently offers up-to-date, professional therapeutic systems along with Home Units for utilization by individuals who have not had their problems resolved by conventional and traditional methods, including surgical procedures. Symptoms generally improve immediately following the institution of Laser Therapy. Applying treatment in a cumulative fashion stimulates the reduction of symptoms over time resulting in the patient’s return to a normal range of activities without the utilization of analgesics or other medications.

Unfortunately Laser Therapy is seldom mentioned as a solution as it is not covered by the codes, insurance programs, national health care systems and other mainstream regulatory bodies. The reasons: medicine is slow to change and vested interests will go to great lengths to provide protection for their products, regardless of the lack of value induced.

At this point in time, it must be clearly understood that the BioFlex Laser Therapy Systems offer ongoing relief of symptoms of arthritis in all areas of the body by restoring the normal morphology and function of the cells. In addition the therapy provides a potent anti-inflammatory effect and boosts the immune system while restoring the integrity of the cells. Regeneration of cartilage is also a part of this process, which is administered in a pain-free and completely safe manner. Comparatively speaking, the cost is minimal and each treatment stimulates the healing process to a higher level, making surgical interventions such as arthroscopy, joint replacements and spinal surgeries in the majority of instances redundant. As time
progresses the patient can discard all pharmaceuticals and focus on a healthy diet and activities such as swimming, stretching, walking to achieve a complete recovery.

The facts regarding the efficacy of Laser Therapy are undeniable. At our Meditech Rehabilitation Clinics, this reality can be seen many times many times over the course of each day and the changes which patients often describe as “a miracle”, have come to be the standard outcome.

A recent example of results achievable is the case of Jerome Williams, also known as “].Y.D.” or Junk Yard Dog, a brand label that he has acquired over a stellar ten year career in the NBA. Jerome presented for treatment at one of our clinics in April and immediately noted improvement. He acquired a Home System and a month later, a Professional System for stationary therapy at his home in Las Vegas, Nevada. The results achieved have been so dramatic that at the age of 44, he has returned to a professional career in basketball in the newly formed 3D League.

Once again, his play is outstanding and in addition he is continuing his long-standing career with the NBA as a good will ambassador of the league. J.Y.D. is also involved in many charitable and educational organizations in his post-NBA career. I am pleased to state that he is a perfect example of what can be accomplished with the intelligent application of BioFlex Laser Therapy, a technology that can replace all current and conventional treatments for arthritis. For additional information, contact Meditech International Inc., Toronto, Canada (416-251-1055), or review our website (www.bioflexlaser.com).

Junk Yard Dog Sees The Light

‘Jerome ‘JYD’ Williams has two BioFlex Laser Therapy Systems… and he’s protecting them like a Junk Yard Dog with a bone.’

Former NBA star and currently on the Power Team of the Big 3 Basketball League, Jerome “Junk Yard Dog” (JYD) Williams relies on BioFlex Laser Therapy to eliminate the pain in his knees. The latter was not only chronic but at times acute, preventing Jerome from playing basketball, the sport that is relevant to his sense of completeness in life. After just two months of self-administered therapy, the pain was relieved to the degree that he was able to resume his professional basketball career in the 3-on-3 league, demonstrating his high level abilities while playing along with other notable former NBA stars. He travels with a BioFlex Personal System on the road and uses a Professional System at home.

treatment1

pic1

Top: Jerome being treated with the BioFlex DUO+ Treatment Array
Bottom: Jerome performs in the 3up League

Jerome attended Georgetown University on a full athletic scholarship and as a further testament of his tremendous athletic ability, was picked in the 1st round of the NBA’s 1996 Draft by the Detroit Pistons. His impressive career as an NBA Power Forward spanned nine years with Detroit, the Toronto Raptors, the Chicago Bulls and the New York Knicks. . At all times, he demonstrated his ability to be a team player and in 2000, he led the league in high rebounding percentages and was ranked third overall in offensive ratings.

Jerome Williams brought his talent, heart and extraordinary passion to the court and holds an impressive 6.6 points per game and 6.4 rebounds. His NBA career included a total of 587 games. Nicknamed “JYD” for his extraordinary work ethic by his teammates in Detroit, he furthered the JYD persona into his own brand.

JYD was excited to join the Toronto Raptors in 2000; so much so that he passed up a morning flight, electing instead to brave a brutal February snowstorm and drive from Detroit to Toronto the night before. He wanted to make certain that he was in the city in time for his first practice with his new teammates.

Toronto fans were jubilant on his arrival. The greetings at the Air Canada Centre by the fans when he played as a Raptor for the first time were overwhelming. Toronto Raptor fans continued to show their love even after JYD was traded, always providing a standing ovation whenever he was on the court.

His impressive NBA career and work ethic, matched by his stellar character, continues to be demonstrated by his involvement in many charitable organizations and his work as a good will ambassador for the NBA.

He initiated an after-school program in the Brewster community in Detroit “right in the middle of the projects”, devoting extensive time and effort to this task.

In an effort to bring his unparalleled knowledge and understanding of the game of basketball to underdeveloped nations, he joined “Basketball Without Borders”. Jerome’s post-NBA career is highlighted by numerous community service awards over the years. He was honoured with a National Home Team award by the Fannie Mae Foundation, was invited to the White House and led a drive to raise money for the Toronto District School Board to buy books for students. His passion to give back to the community was recognized by the NBA principals and he was awarded the NBA Community Assist Award in May 2005. A father of four, he currently serves as Chairman of the non-profit organization, JYD Project Inc. Although Jerome celebrated many firsts as an NBA player, he was the first role player, featuring his own tennis shoe and a Sprite deal.

Incidentally, he is not the first NBA star to rely on BioFlex Laser Therapy systems but he is no doubt the most grateful and enthusiastic individual with regard to the effectiveness of the treatment. As he recalls, many of his Toronto Raptor teammates, including Vince Carter, Tracy McGrady, etc. relied upon this amazing technology to treat their many injuries. Feel free to enter Jerome’s DoggPound but with the BioFlex Systems in his healthcare arsenal, don’t ever expect to hear the Junk Yard Dog whimper.

From my interactions with Jerome, he is an outstanding human being, a basketball player for the ages, a solid family man and someone who cares about everyone inhabiting our planet. His existence makes the world a better place. I am certain he will bring all of his stellar qualities to the Big 3 League and entertain everyone that has the privilege and opportunity to watch him perform.

dr_kahn_jerome_williams

Jerome Williams with Dr Kahn at the Meditech Downtown Clinic

Traumatic Brain Injury– A Commentary

RETHINK-REDO-REWIRED-BOOK-COVER-1150x1721Anthony Aquan-Assee, M.Ed. recently presented me with a book titled “Rethink, Redo, Rewired”. The book is an excellent treatise devoted to the course of recovery from a series of major brain injuries. The book describes Anthony’s prolonged struggles to regain his life, along with the many impediments and inappropriate therapies that litter the path to recovery.

On pages 65-68, he describes his experience with Laser Therapy, which played the major role in his return to normal health. Personally, I can state unequivocally that all cases of traumatic brain injury treated at our clinic, more than 80% achieve this level of recovery and the remainder are improved in varying degrees. During the year 2016, we treated over 500 cases of traumatic brain injury and this year, our expectations are that we will exceed 800 patients treated at the Meditech Rehabilitation Clinics.

The book confirms that Anthony has made a relatively complete recovery from the injuries sustained during the past decade. He is fully functional and once again making contributions to our society in a normal fashion.

His case is just one example of the numerous patients that we return to a normal health status after struggling for many years in the black void of traumatic brain injury.

To learn more or purchase a book, visit https://anthonyaquan-assee.com

Case Study: Erythromelalgia/Reynaud’s Phenomenon

The patient is a 71-year-old female Ph.D. who presented at our clinic 18 months ago complaining of edema, pain and multiple ulcers of both feet. The lower extremities demonstrated a marked erythematous/cyanotic discolouration that existed at all times.
The pain was frequently excruciating and ambulatory activities were minimal.

The diagnosis of her condition had been established at age 20 years. Over time, painful nodules developed on the skin of the lower extremities and these would periodically rupture, leading to the formation of recurrent ulcers. Symptoms were aggravated by elevation of ambient temperatures above 19°C.

The patient was unable to wear socks, shoes or tolerate any piece of clothing that had prolonged contact with the skin. She was forced to keep the ambient temperature at her home at a constant 20°C in order to be relatively comfortable. She was unable to take walks, particularly during the summer, as she was not able to tolerate elevated temperatures and the resulting induced pain.

The formation of multiple ulcers of the lower extremities complicated her condition. Her hands were only minimally to moderately affected and demonstrated mild erythema. The dermal ulcers were most pronounced over the plantar aspects of the feet and sometimes involved the toes and the dorsum also.

The patient is a non-smoker and worked as a principal researcher in the field of psychology.

Periodically she took Cymbalta (duloxetine) and Lyrica (pregabalin) in titrated dosages.

PHYSICAL EXAMINATION: At the time of her initial presentation, both feet were cold to the touch and demonstrated marked tenderness to palpation.
Multiple ulcers were noted over the plantar aspects of both feet and some of these showed marginal epithelialization.
There was significant acute inflammation over the soles of both feet.
A moderate degree of edema, extending to the ankle, was present.
The erythematous/cyanotic disolouration was pronounced.
Peripheral arterial pulses were within normal limits.

TREATMENT: A course of treatment was initiated using the BioFlex Laser Therapy System. This was continued in the office three times per week using the Professional System. Treatment included application to the lumbar spine (autonomic nervous system), and locally in circumferential fashion around the ankles and feet.

Appropriate protocols were developed over 2.5 months and these were transferred to a Home Unit for application at the patient’s home two more times each week. The patient was last seen in our office on July 4, 2017. The edema had disappeared completely, along with the sensitivity. Discolouration was minimal. There were a few areas of thickening of the dermis over the plantar aspects of both feet but there was no tenderness and no evidence of ulceration.

The patient is now able to walk normally, work in the garden and activity levels are relatively normal. She has some minor sensitivity to temperature changes but she is able to control that to a significant degree. In essence, there has been over 90% overall improvement with regard to both symptoms and physical findings. Prior to the institution of Laser Therapy, numerous medications and other therapies had been utilized, none of which provided any benefit.

This case demonstrates what can be achieved utilizing the correct application of Laser Therapy to a compliant patient.

Erythromelalgia, also known as Mitchell’s disease, is a rare vascular peripheral pain disorder in which blood vessels, usually in the lower extremities or hands, are episodically blocked (frequently on and off daily), then become hyperemic and inflamed. There is severe burning pain (in the small fiber sensory nerves) and skin redness. The attacks are periodic and are commonly triggered by heat, pressure, mild activity, exertion, insomnia or stress. Erythromelalgia may occur either as a primary or secondary disorder (i.e. a disorder in and of itself or a symptom of another condition). Secondary erythromelalgia can result from small fiber peripheral neuropathy of any cause, polycythemia vera, essential thrombocytosis,[1] hypercholesterolemia, mushroom or mercury poisoning, and some autoimmune disorders. Primary erythromelalgia is caused by mutation of the voltage-gated sodium channel α-subunit gene SCN9A.
In 2004 erythromelalgia became the first human disorder in which it has been possible to associate an ion channel mutation with chronic neuropathic pain; when its pathophysiology was initially published in the Journal of Medical Genetics.

Primary erythromelalgia may be classified as either familial or sporadic, with the familial form inherited in an autosomal dominant manner. Both of these may be further classified as either juvenile or adult onset. The juvenile onset form occurs prior to age 20 and frequently prior to age 10. While the genetic cause of the juvenile and sporadic adult onset forms is often known, this is not the case for the adult onset familial form.

The most prominent symptoms of erythromelalgia are episodes of erythema, swelling, a painful deep-aching of the soft tissue (usually either radiating or shooting) and tenderness, along with a painful burning sensation primarily in the extremities. These symptoms are often symmetric and affect the lower extremities more frequently than the upper extremities. Symptoms may also affect the ears and face. For secondary erythromelalgia, attacks typically precede and are precipitated by the underlying primary condition. For primary erythromelalgia, attacks can last from an hour to months at a time and occur infrequently to frequently with multiple times daily. Common triggers for these episodes are exertion, heating of the affected extremities, and alcohol or caffeine consumption, and any pressure applied to the limbs. In some patients sugar and even melon consumption have also been known to provoke attacks. Many of those with primary erythromelalgia avoid wearing shoes or socks as the heat this generates is known to produce erythromelalgia attacks. Raynaud’s phenomenon often coexists in patients with Erythromelalgia. Symptoms may present gradually and incrementally, sometimes taking years to become intense enough for patients to seek medical care. In other cases symptoms emerge full blown with onset.

Primary erythromelalgia is a better understood autosomal dominant disorder. The neuropathological symptoms of primary erythromelalgia arise from hyperexcitability of C-fibers in the dorsal root ganglion. Specifically, nociceptors (neurons responsible for the sensation and conduction of painful stimuli) appear to be the primarily affect neurons in these fibers. This hyperexcitability results in the severe burning pain experienced by patients. While the neuropathological symptoms are a result of hyperexcitability, microvascular alterations in erythromelalgia are due to hypoexcitability. The sympathetic nervous system controls cutaneous vascular tone and altered response of this system to stimuli such as heat likely results in the observed microvascular symptoms. In both cases, these changes in excitability are typically due to mutation of the sodium channel NaV1.7. These differences in excitability alterations between the sympathetic nervous system and nociceptors is due to different expression of sodium channels other than NaV1.7 in them.

Erythromelalgia is a difficult condition to diagnose as there are no specific tests available. However, reduced capillary density has been observed microscopically during flaring; and reduced capillary perfusion is noted in the patient. Another test that can be done is to have the patient elevate their legs, and note the reversal (from red to pale) in skin color. Tests done at universities include quantitative sensory nerve testing, laser evoked potentials, sweat testing and epidermal sensory nerve fiber density test (which is an objective test for small fiber sensory neuropathy). Due the aforementioned factors, patients may face delays in diagnosis.

Some diseases present with symptoms similar to erythromelalgia. Complex regional pain syndrome (CRPS), for instance, presents with severe burning pain and redness except these symptoms are often unilateral (versus symmetric) and may be proximal instead of purely or primarily distal. Furthermore, attacks triggered by heat and resolved by cooling are less common with CRPS.
Primary erythromelalgia management is symptomatic, i.e. treating painful symptoms only. Specific management tactics include avoidance of attack triggers such as: heat, change in temperature, exercise or over exertion, alcohol and spicy foods. This list is by no means comprehensive as there are many triggers to set off a ‘flaring’ episode that are inexplicable. Whilst a cool environment is helpful in keeping the symptoms in control, the use of cold water baths is strongly discouraged. In pursuit of added relief sufferers can inadvertently cause tissue damage or death, i.e. necrosis. See comments at the end of the preceding paragraph regarding possible effectiveness of plastic food storage bags to avoid/reduce negative effects of submersion in cold water baths.
One clinical study has demonstrated the efficacy of IV lidocaine or oral mexilitine, though it should be noted that differences between the primary and secondary forms were not studied. Another trial has shown promise for misoprostol, while other have shown that gabapentin, venlafaxine and oral magnesium may also be effective,[5] but no further testing was carried out as newer research superseded this combination.

Strong anecdotal evidence from EM patients shows that a combination of drugs such as duloxetine and pregabalin is an effective way of reducing the stabbing pains and burning sensation symptoms of erythromelalgia in conjunction with the appropriate analgesia. In some cases, antihistamines may give some relief. Most people with erythromelalgia never go into remission and the symptoms are ever present at some level, whilst others get worse, or the EM is eventually a symptom of another disease such as systemic scleroderma.

The patient elected to have treatment with the BioFlex Light Therapy System. The technology is utilized to treat a multitude of conditions that require healing along with the relief of pain and the reduction of inflammation. In addition, Laser Therapy attempts to restore normal cell function. Her condition responded to Light Therapy during which the photons emitted are absorbed by mitochondrial chromophores within the cell. Consequently electron transport, adenosine triphosphate (ATP) nitric oxide release, blood flow, and reactive oxygen species increase and diverse signaling pathways become activated. Stem cells can be activated to permit tissue repair and result in healing. In dermatology, Laser Therapy has beneficial effects on scarring, burns, and other damage to the dermis. Furthermore, Laser Therapy can reduce ultraviolet damage both on a preventative and therapeutic basis. In pigmentation disorders such as vitiligo, Laser Therapy can increase pigmentation by stimulating melanocyte proliferation and reduce deep pigmentation by inhibiting autoimmunity. Inflammatory diseases such as psoriasis and acne can also be helped to a significant degree. The non-invasive nature and almost complete absence of side-effects encourage therapeutic benefits in dermatological practice.

Laser therapy has also been shown to reduce inflammation and edema, induce analgesia, and promote healing in a range of musculoskeletal pathologies. The peripheral nerve endings of nociceptors, consisting of the thinly myelinated A∂ and unmyelinated, slow-conducting C fibers, lie within the epidermis. This complex network transduces noxious stimuli into action potentials. Moreover these nerve endings are very superficial in nature and thus are easily within the penetration depths of the wavelengths used in Laser therapy. The cell bodies of neurons lie within the dorsal nerve root ganglion, but the elongated cytoplasm (axons) of the neurons extends from the cell body to the bare nerve endings in the surface of the skin. The direct effect of Laser therapy are initially at the level of the epidermal neural network, but the effects move to nerves in subcutaneous tissues, sympathetic ganglia, and the neuromuscular junctions within muscles and nerve trunks. Laser therapy applied with a sufficient level of intensity causes an inhibition of action potentials where there is an approximately 30% neural blockade within 10 to 20 minutes of application, and which is reversed within about 24 hours. The laser application to a peripheral nerve does have a cascade effect whereby there is suppressed synaptic activity in second order neurons so that cortical areas of the pain matrix would not be activated.

Adenosine triphosphate (ATP) is the source of energy for all cells, and in neurons this ATP is synthesized by mitochondria while they are located in the dorsal root ganglion. These mitochondria are then transported along the cytoskeleton of the nerve by a monorail system of molecular motors. Laser therapy acts like an anesthetic agent, in that both Laser therapy and anesthetics have been shown to temporally disrupt the cytoskeleton for a matter of hours as evidenced by formation of reversible varicosities or beading along the axons, which in turn cause mitochondria to “pile up” where the cytoskeleton is disrupted. The exact mechanism for this effect is unknown but it is not a thermal action. It has been shown that Laser therapy at the correct dose decreases mitochondrial membrane potential (MMP) in DRG neurons and that ATP production is then reduced so perhaps the lack of ATP could be cause of this neural blockade. The most immediate effect of nociceptor blockade is pain relief which occurs in a few minutes and has been shown by the timed onset of a conduction blockade in somatosensory-evoked potentials (SSEPs). This inhibition of peripheral sensitization not only lowers the activation threshold of nerves but also decreases the release of pro inflammatory neuropeptides (i.e. substance P and CGRP). In persistent pain disorders this reduction of tonic input to activated nociceptors and their synaptic connections, leads to a long-term down-regulation of second-order neurons. The modulation of neurotransmitters is a further possible mechanism of pain relief, as serotonin and endorphin levels have been shown to increase in animal models and following laser treatment of myofascial pain in patients. Thus Laser therapy can have short, medium and long term effects. Fast acting pain relief occurs within minutes of application, which is a result of a neural blockade of the peripheral and sympathetic nerves and the release of neuromuscular contractions leading to in a reduction of muscle spasms.

In the medium term there is a decrease of local edema and a reduction of inflammation within hours to days. The action of Laser therapy in reducing swelling and inflammation has been well established in animal models as well as in clinical trials. The numbers of inflammatory cells has been shown to be reduced in joints injected with protease, in collagen-induced rheumatoid arthritis, and in acute pulmonary inflammation. The expression levels of pro-inflammatory cytokines have been shown to be reduced by Laser therapy in burn wounds, in muscle cryo lesions and in delayed type hypersensitivity. The long term effects of Laser therapy occur within a week or two and can last for months and sometimes years as a result of improved tissue healing.
This case profile has demonstrated marked improvement of symptoms since the patient commenced Laser Therapy. There are no lesions existing currently and the toenails of both feet have grown back normally and appear to be healthy. She has a mild degree of discomfort with elevated ambient temperatures but can now tolerate wearing open-toed sandals and is able to engage in most physical activities without discomfort. She continues to use a Home Laser Therapy System periodically and finds this to be a most satisfactory arrangement.

Case Study

June 30, 2017

This patient is a 61-year-old retired geophysicist who resides in Texas. She has a long history of pain in the cervical and lumbar spine pain areas, with severe sciatica on the left side and moderate pain in the left upper extremity for an extensive number of years. Her symptoms have been relatively acute since 2013.

Prior to initiating treatment, an MRI of the lumbar spine was performed by her family physician on March 31, 2014. The radiological diagnosis, aside from degenerative osteoarthritis in both areas, describes a large paracentral disc herniation at L3 causing severe left lateral recess effacement and impingement at the L3 nerve root. This would appear to account for the patient’s severe left-sided radiculopathy.

The patient presented at the Meditech Clinic on June 17, 2016.

The diagnosis established reads as follows: Degenerative Osteoarthritis of the Cervical and Lumbar Spine Complicated by a Disc Herniation L3-4.

The patient had 10 therapeutic sessions on successive days at the Meditech Clinic between June 17-27. She then continued periodic therapy at home utilizing the LED Large Surface Array known as the Duo +180.

By the end of last year, her symptoms has largely disappeared and an additional MRI of the lumbar spine was performed in December 2016. The result—no evidence of any disc herniation. The patient was relatively asymptomatic with only minor pains following excessive activity. She had not required any analgesics in over one year.

Conclusion: This case demonstrates a classic example of the healing effects of Laser Therapy in cases of osteoarthritis with disc herniation resulting in complete resolution of the pathology confirmed by the pre and post treatment MRI’s.

F. Kahn, MD, FRCS(C)

Update re. Major Athletes

Jerome Williams, also known as Junkyard Dog, presented at our clinic approximately two months ago for treatment of both arthritic knees. He initially began therapy utilizing a Home Unit, which he uses for travel, but he subsequently also purchased a Professional System for use at his home in Las Vegas, Nevada.

This week, Jerome reported that his knees were substantially improved and he has returned to playing in the three-on-three professional league for players who have previously played in the NBA. In his first professional game last weekend, he was highly effective and plans to continue playing on a regular basis in this new professional league.

Another success story for BioFlex Laser Therapy Systems that has now become standard in treating high level athletes for acute and chromic injuries.dr_kahn_jerome_williams

Patient Consultation

November 4, 2016

I think that this case best demonstrates what Laser Therapy can accomplish. It truly has unlimited potential and once again this patient is typical of what can be achieved. Needless to say, nothing can be accomplished if you don’t attempt to change the therapeutic approach.

CLINICAL HISTORY: The patient is a female student and a competitive swimmer who sustained a severe contusion injury of the left foot in March of this year. She was diagnosed with complex regional pain syndrome and she now has extreme sensitivity to touch, extending to socks and shoes. She is unable to walk without a pneumatic boot, which holds the lower extremity in a rigid position involving the terminal portion of the left lower extremity.

She has seen multiple specialists including orthopedic surgeons, neurologists and is attending the Regional Pain Management Clinic at Sick Children’s Hospital in Toronto.

Since March, she has been on gabapentin, pregabalin, acupuncture, TENS, physio, massage, chiropractic, etc. She has received no benefit from these therapies.
Pain and generalized discomfort in the left foot and the lower portion of the leg is present 24/7. It is accompanied by a pins and needles sensation, numbness, and excruciating pain on any contact. She is a competitive swimmer, but now is unable to swim at all and even walking is problematic.

PHYSICAL EXAMINATION:

  • The patient holds the left leg below the knee in a fairly rigid position.
  • The right mid-calf is 32 cm in circumference and the left mid-calf is 30 cm.
  • There is marked atrophy of the calf muscles and the small muscles of the left foot. (Photographs taken).
  • Range of motion of the left knee is within normal limits, but also enhances the pain. Range of motion of left ankle is zero.
  • She is unable to dorsiflex, plantar flex, invert or evert the foot, even 1 mm.
  • There is extreme hypersensitivity from a point approximately 3-4 inches above the ankle including the entire foot and toes.

IMPRESSION: Regional Pain Syndrome — Left Foot (Secondary to Trauma.

DISCUSSION:The cause of symptoms could be located anywhere from the cerebral hemispheres to the spinal cord or locally in the left lower extremity. The fact that no improvement has been accomplished with many therapies, the patient’s outlook at this point is bleak indeed.

Some thoughts on this problem: It would appear that the nature of this problem is local, but also involving the neurological system. At some point, the motor nerves to the lower limb have turned off, which brings into play the parasympathetic nervous system.

Therapy must include BioFlex Laser Treatment of local tissue damage in addition to the neurological source including the spinal cord and parasympathetic nervous system. Treatment will therefore be applied locally and over the lumbar spine where the ganglia of the sympathetic nervous system are located.

Summary
Over the course of March to October, approximately 8 months in duration, the patient had extensive visits with a number of- medical specialists, underwent radiological and other studies, and utilized approximately seven different medications along with physiotherapy, etc. She was studied extensively at a University Children’s Hospital and was reviewed by several teams of specialists.
The cost of these therapies were in the $10,000 range and did not improve her status.

At our Laser Rehabilitation Center, she had treatments of the lumbar spine and the extremity involved on a Sunday, Monday and Tuesday. At this point, her symptoms were resolved over 90%. Over the next 2-3 weeks, she received some additional therapy with a complete resolution of all symptoms.

The patient has been able to resume her swimming as previously and is functioning in a normal manner in all respects. There has been no recurrence.
it should be noted that at Meditech, we treat at least one patient daily with what her mother has termed as “a miracle”.

Final Comments Re: –Theralase Questionnaire

Enclosed in this communication are the responses offered by four knowledgeable and experienced clinicians for your review.

Ongoing efforts to denigrate a superior product by the infusion of false rhetoric brings to mind the growing trend of the dissemination of false information, something that is becoming a serious problem in our culture. This is reinforced by the age old dictum that the lie oft repeated may eventually become the truth.

On that note, a recent Time magazine cover questions “Is the Truth Dead?” Further confirmation of this state of affairs was well depicted in a recent episode of 60 Minutes, describing the extensive circulation of false information on the internet, social media and other channels of communication. This trend, similar to the questionnaire, threatens the integrity of our methods of communication and potentially our civilization. It was interesting to learn that individuals engaged in this type of activity fund other companies to post reinforcements on additional websites, specifically designed to perform this service. The perpetration of this type of activity has become a major enterprise, often designed to destroy a competitor or to gain competitive advantage.

In a recent editorial by Robin V. Sears in the Toronto Star, it is stated that Lenin, who allegedly said that an insistence on “telling the truth is merely a bourgeois prejudice” lauded the strategic value of lies. He was also purportedly the author of the timeless insult to naïve Soviet fellow travelers as “useful idiots”. Not surprisingly, Putin reveres Lenin openly.

Whereas all of these activities demonstrate various degrees of spreading information designed to mislead, seldom does a rebuttal occur. The result—a new form of white-collar crime is perpetrated without challenge, often anonymously, yet no one takes the time or trouble to rectify these matters. Governments and the judiciary, unless directly affected, do not seem to care and for small organizations, a response can be time consuming and costly.

Nevertheless, from our perspective, it is of the utmost importance that this type of activity must be opposed, particularly in the field of science and medical practice. In these areas, it is imperative that a rigorous standard of truth be maintained and vigorously defended.

At this time, I consider this matter closed and if any further clarification is required, address all inquiries to Richard Bramer, Director of Communications at Meditech International Inc.

Dr. Ben Yuen Writes:

Having reviewed Theralase’s questionnaire and the misleading answers, it is clear that the company has a minimal understanding of the effects of bio-photo therapy on tissues and internal organ systems.

The efficacy of light therapy depends on a number of factors including wavelength, frequency, duration, total tissue exposure, location of the pathology and the neuro-musculo-immuno relationship of the condition being treated.

Theralase’s claim of providing better tissue response with deeper penetration using a narrow laser beam has one overriding and major shortcoming; a narrow beam lacks the ability to produce an extensive photodynamic effect on tissues that are widely inflamed compared to the high level of efficacy consistently demonstrated by the BioFlex arrays.
How deeply the light penetrates is just one key factor of success. If it were, as Theralase indicates, then how do we explain the phenomenon of simple exposure to full spectrum light in reversing Seasonal Affective Disorder by stimulating the brain’s production of the neurochemicals responsible for a positive mood? This is just one example of many that explains the success of BioFlex Laser Therapy.

To not take into consideration the many pertinent factors, except penetration, demonstrates a marked deficiency in the understanding of the application of light/laser therapy.

Just as there are studies to state the effectiveness of 660 nM and 905 nM, there are even more studies to demonstrate the benefits of using 800 to 850 nM. There is no scientific evidence to support the claim that 905 nM is superior. Moreover, according to a number of respected, independent authors, much of the 905 nM wavelength is absorbed by water in the tissues, where it has no healing effect. One must also take into consideration that with the application of bio-photo therapy, the genetic difference of each individual patient must be considered. Some patients require longer exposure while others do not.
BioFlex’s software driven programs allows not only for standardized applications but also for individual customization which is a major factor in obtaining maximum effect.

It should also be noted that the BioFlex software driven program consistently delivers precise dosages with respect to all of the therapeutic parameters reflected in the protocols. Theralase, on the other hand, has minimal ability to accomplish this highly specific requirement.

The BioFlex array is completely capable of treating multiple areas simultaneously and this is highlighted both in their software and Clinical User’s Manual. As a Laser Medicine practitioner treating a high volume of patients over the past 15 years, to the best of my knowledge no other manufactured device can deliver comparable therapeutic effects to the BioFlex products.

Sincerely,

Dr.Benjamin Yuen
165 Hammonds Plains Road
Bedford, Nova Scotia B4A 4C7
Tel: 902-835-6699 Fax: 902-835-7771

Len Rudnick Postulates:

THE TRUTH, THE WHOLE TRUTH OR PERHAPS NOT QUITE THE TRUTH

In October 2016, Theralase sent a questionnaire (I am being kind in calling it that) to BioFlex practitioners. In my opinion, it was an act of desperation to use bribery to get a provider’s attention. Frankly, I was embarrassed for Theralase in reviewing this document.

In an effort to provide truth and transparency, I can state categorically that I have used BioFlex equipment exclusively for the last 20 years. Previously I had used the products of many other manufacturers (too many to name) and since switching to BioFlex, I confess that I do have a LOVE relationship with all aspects of the company’s principals and functions. This includes Dr. Kahn, Slava Kim and the entire staff including their service department, and yes, all equipment requires occasional servicing.

I have always been of the firm belief that the measure of a company and its product(s) is how you are treated after you have paid for the equipment. I would use BioFlex as a role model for this criteria in every respect.

Theralase mentions approximately 25 scientific articles showing that their laser diodes are superior to LED’s. I can show even more objective scientific peer-reviewed articles that state an opposite view. In fact BioFlex, at one of its international conferences, had a keynote speaker from Sweden whose book picks apart that and other peer-reviewed research. As always, those conferences were educational, timely and well-received by a community that required unadulterated information. Theralase asks what amount of time is necessary for treating while using BioFlex equipment. The correct answer is this depends on the pathological condition, its severity, the age of the patient, the pigmentation of their skin and the morphology of the cells. Theralase is incapable of considering any of those factors or adjusting for them. In healthcare, one size definitely does not fit all.

In addition, one should be aware that BioFlex has preset protocols for most diseases and has the ability to customize as required, taking into consideration the above mentioned criteria. Moreover, it is primarily a therapy that does not require constant attendance, freeing the practitioner to perform other duties while still providing Laser Therapy for those under treatment. The description of the BioFlex equipment using primarily LED’s and a single laser diode is consistent with Theralase’s policy of presenting anything but the truth. BioFlex in fact historically has made available three different single laser diodes and individual probes which incidentally can be modulated with regard to many parameters. They consist of the LDI 75, LDR 100 and the LDI 200 mW; each has its specific use. Again, one size does not fit all with BioFlex equipment or their patients. Before the probes were available, I simply used the LED-based treatment arrays with excellent results; better than most manufacturer’s equipment that utilized poorly engineered and manufactured laser diodes. In fact, clinically there is no difference when using LED’s compared to using just laser diodes. Utilizing the arrays and diodes in proper sequence is the most effective method of applying effective treatment and this is what separates BioFlex products from others, aside from their thorough understanding of cellular pathologies.

The truth about the basic science guiding application should be based on clinical outcomes rather than the size or power of the device. I know from personal professional experience as I was one of the first to use the Microlight, Omega, Q1000 Erchonia and other laser diode devices. I actually obtain superior results with more disease entities using BioFlex equipment. I can unequivocally state that BioFlex Systems are the devices of choice.

At the fourth annual International Laser Therapy Conference in Toronto, Canada, in 2006, one of the presenters was Dr. Chukukah Enwemeka. His bio stated among other things that he was the author at that time of 50 research papers, monographs and he had written many chapters in books on Laser Therapy. He has presented over 200 seminars, symposium workshops including 80 invited international presentations in 28 countries. Worldwide, Professor Enwemeka was then and still is one of the foremost authorities on lasers and light-based treatment technology. During a question and answer session after his initial presentation, I stated that it was my observation from experiencing clinical outcomes that patients had better results using red and infrared treatment arrays in sequence then combined wavelengths. His response was that it wasn’t just my observation and that there exists a preponderance of scientific evidence that multiple wavelengths delivered simultaneously interferes with the physiology of the healing process once they penetrate the dermis.

By the way, yes the BioFlex Professional System can treat two different areas simultaneously. I would be interested to know if Theralase has had a clinical research facility for more than 20 years and I would also like to know if they, at their research facilities, have collected patient treatment data on several hundred thousand patients. I would like to know further if they regularly update their equipment protocols based on the findings from that data, if it exists.
I know from long-standing personal experience that the answers to the above questions are absolutely yes on all accounts for Meditech and their BioFlex products. The principals at Theralase should take note that prevarication, disinformation and inappropriate criticism of the leading company in the Laser industry are not the keys to success.

Leonard Rudnick, DC
Laser Therapeutics
Tucson, Arizona

Dr Nathan Cheung States:

During the course of my educational process, I had some exposure to Laser Therapy devices manufactured by a variety of companies. None appeared to be overwhelming from a therapeutic perspective.

In early 2014, I enrolled in the Certification Course at Meditech and was fascinated by what I saw, heard and learned by attending the Meditech Rehabilitation Clinic for a number of weeks. Although I was initially a skeptic, I quickly learned that there was no deception involved and was thoroughly impressed by the assessment process and practice at the clinic and even more so by the treatments applied. As a result, I joined a Laser Therapy clinic and the results achieved continue to amaze me, along with the gratitude expressed by patients.

I was therefore astounded to receive the Theralase questionnaire in October 2016, along with a generous bonus of free Starbucks coffee. Immediately I sensed two problems; disinformation and deception, not appeased by the Starbucks products. In view of this, I wish to independently set the record straight for those who are not acquainted with either Theralase or the wonderful BioFlex System.

I interpret Theralase’s efforts to discredit Meditech as designed to boost their minimal sales and further confuse practitioners who do not fully understand the complex area of physics, cellular pathology, etc. Below you will see the real answers to the misleading questions posed by Theralase and their contrived answers.

Question 1
In certain circles the debate of utilizing superluminous diodes versus laser diodes remains controversial. The degree of coherence, between these two types of light, is continually being exploited to falsely claim that one is ultimately more effective than the other. In the treatment of biological tissue using LEDs, coherency is not lost but only reduced after dermal penetration; laser speckles are still formed in tissue (Hode et al, 2009). This clearly supports the use of superluminous diodes as being equally efficient in the treatment of cells. The singular difference, with laser diodes, is that the power output is generated in a confined area resulting in deeper penetration. However, the combination of LEDs in large treatment arrays and laser diodes in proper sequence allows for a wider range of varying penetration depth and absorption by cells.

The Bioflex Laser Therapy systems utilize both superluminous diode (LED) arrays and laser diodes from 660 to 840 nm wavelength. These systems are carefully engineered and require specific light-emitting diodes capable of delivering an accurate and reproducible photon stream with every treatment session. LEDs utilized are explicitly customized and only available in the Bioflex treatment arrays. In addition, Meditech has always believed in the co-operation between the patient and the clinician. This very important interaction allows for the development of individualized treatment protocols that are specific to each patient and each health issue. This innovative method of laser therapy permits us to consistently achieve a high level of relief in the majority of patients treated.

Hode T., Duncan D., Kirkpatrick S., Jenkins P. and Hode L. (2009) The importance of coherence in phototherapy. Proc. SPIE 7165, Mechanisms for Low-Light Therapy IV, 716507 (February 18, 2009); doi:10.1117/12.809563

Question 2
The Bioflex Laser Therapy systems use scientifically proven wavelengths to reduce inflammation, accelerate healing and stimulate the regeneration of cells. Studies have shown that optimal healing can only be achieved when laser therapy is applied specifically within the 613.5-683.7 nm range for red light and 812.5-846 nm range for infrared light (Karu and Kolyakov, 2005). In addition, a recent study has proven the depth penetration of light at 810 nm through muscle and skin and is greater than superpulsed light transmitted at 904 nm (Anders and Wu, 2016).

Karu T.I. and Kolyakov S.F. (2005) Exact action spectra for cellular responses relevant to phototherapy. Photomedicine and Laser Surgery. 23(4), 355-361.

Anders J. and Wu X. (2016) Comparison of light penetration of continuous wave 810nm and superpulsed 904nm wavelength light in anesthetized rats. Photomedicine and Laser Surgery. Vol. 34, No, 9: 418-424

Question 3
Bioflex treatment protocols have been carefully developed over the past 25 years by incorporating research, scientific knowledge and clinical expertise. The duration of treatments are specific to the area and the injury and have been developed to allow for optimal photon saturation; shorter treatment times are unable to generate the same effect.

Question 4
The Meditech Duo System can treat two areas at the same time. By using multiple systems, up to four areas can be treated on any patient simultaneously.

Question 5
All Bioflex Laser Therapy Systems come with a standard 2-year warranty. In addition, Meditech offers clinical and technical support 7 days per week from experienced clinicians, laser therapists and engineers. Access to marketing resources are readily available on the website. Additionally, with the purchase of a Bioflex Laser Therapy System you will have the option of listing your clinic on the website as a certified Bioflex Laser Therapy provider.

Dr. Nathan Cheung

The Theralase questionnaire states that it wants to be fair. I think that anyone who has the capacity to read understands that is the last thing they want to be, even if they were able to comprehend such an approach.

BioFlex uses large surface LED arrays which deliver both red and infrared light in sequence. Subsequently as clinically indicated, two laser probes are provided, one red 100 mW followed by an infared laser probe 200 mW. These again may be used in sequence in order to provide optimal healing capability. All arrays and probes can be widely adjusted with regard to power settings, duty cycle and other modulations which are somewhat complex. Protocols are provided in standardized form for most disease entities and the customization mode permits a wide range of individualized protocols, in order to facilitate the desired outcome.

The LED’s utilized in all BioFlex Systems are manufactured to our specifications by a company that performs this exclusively for Meditech. Our diodes, both LED’s and the Laser variety, are comparatively expensive however, at Meditech no sacrifice is too great in the interest of quality and all treatments are designed to provide maximum benefit. Most manufacturers use inexpensive, off-the-shelf equipment, particularly Laser diodes that are vastly inferior in quality and output. Moreover, they are highly degradeable. I stress that these factors are of extreme importance.
BioFlex Systems use wavelengths including 660, 830 and 840 nM and these have been found to be most effective from the clinical perspective. An extensive number of basic research and scientific articles have been produced by individuals such as Dr. Tiina Karu, Dr. Mary Dyson, Dr. Chukuka Enwemeka and others with regard to these matters. These have been referenced previously, as you will recall, Dr. Tuner, in his article previously submitted, indicates that a 905 nM wavelength is of minimal value, as the majority of light is absorbed by water, a significant component of all tissues.
BioFlex Laser Therapy Systems can be configured to treat multiple areas simultaneously and current prototypes will improve that aspect of delivery. Using several systems, multiple body areas can be treated at the same time.
A small percentage of patients will improve with most treatments of brief duration, no matter what power settings are used. If they do get better, rest assured that it is solely the result of the organism’s natural healing propensities and should not be attributed to anything else.

No LED or laser diode can force cells to heal and the application of inappropriate wavelengths of whatever power for short periods of time is of minimal benefit to tissue healing. The Arndt-Schulz law confirms compilation of proper dosages.

A significant body of clinical research based on studies conducted on cells both in vivo and cell cultures indicate without equivocation that duration, wavelength and other modulations must be carefully selected for optimal cell recovery.

It should be noted that at Meditech, we continue to provide high percentage cure rates for spinal stenosis, non-healing wounds, etc. in the majority of cases treated. In addition, during 2016 we have treated over 500 patients suffering from cerebral concussion, both chronic and acute, with an unparalleled level of improvement/cure rate.
As with the four preceding questions, the final question is also false but only by 350%; better than the answers provided to the other four.

Meditech/BioFlex offers a standard two year warranty and makes available an extended warranty for five additional years.

In summation, all the questions posed are inappropriate, are posed in a deceitful manner, demonstrate a lack of basic understanding of Laser Therapy and have no relationship to scientific fact.

Undoubtedly they are designed to attempt to boost Theralase sales, which are minute compared to BioFlex Systems.

The latter are currently being utilized in over 60 countries worldwide and the company provides an educational program to over 1000 healthcare professionals annually through certification seminars, webinars, etc.

BioFlex Therapy Systems are designed by clinicians for clinicians in conjunction with engineers who are qualified in many disciplines.

Meditech officials welcome any further queries with regard to the questionnaire that you received last October and is prepared to forward independently sourced scientific literature to confirm the truth in all matters stated.

dr kahn signature 2015-01

Fred Kahn, MD,FRCS(C)

Communication to All Laser Medicine Practitioners

In October of 2016, Theralase, a small Laser Therapy company located in Toronto, distributed a questionnaire to BioFlex Laser Medicine Practitioners. Several recipients were confused with regard to the origin of this document. This is understandable as it is a thinly disguised effort to make it appear to have originated at Meditech. I can assure you that this was not the case and unfortunately, this demonstrates the characteristics of some industry principals – projecting a blend of hucksterism, hype, disinformation and deception.

Most significantly, the questionnaire reflects the lack of clinical understanding that prevails within some Laser Industry Manufacturers, as reflected by their literature, press releases, etc., best described as pseudoscience. These communications perform a disservice to the legitimate sector of Laser Medicine, aside from the paucity of comprehension of clinical pathologies and the inappropriate design of devices required to resolve the latter. All manufacturers must focus on the design and building of machines to relieve the many problems that exist, instead of simply building devices to generate profits. Without fully understanding these realities and objectives, their efforts will continue to be self-defeating.

Prior to responding to the five questions included in the questionnaire, we will attempt to provide some overall perspective to this entire situation. Moreover, we regard this as an opportunity to expand the educational process that is so important in qualifying and empowering Laser Therapists.

At this time, at least three knowledgeable and respected medical practitioners, offended by the Theralase comments, have offered to respond to the questionnaire and these reports will be delivered to you sometime in April.

At Meditech, we are reluctant to advertise however we make efforts to share information reflecting current basic research and engineering improvements, many of which are integrated into the systems we manufacture, along with new, effective clinical applications. We prefer to leave the evaluation of our technology and the clinical results achieved to others who have the ability to independently comment on our body of work and how it is affecting current medical practice. To wit:

    • Dr. Norman Doidge’s book, “The Brain’s Way of Healing”, which was published in 2015, devotes an entire chapter to BioFlex Laser Technology and this text still resonates with the medical and lay community in many parts of the globe.

 

    • In 2015, an Australian TV network filmed our activities over the course of two weeks and developed a documentary, extoling our technology in Australia, New Zealand, Tasmania and adjacent regions. The network called Seven Network Limited is similar to the U.S. program, 60 Minutes.

 

    • In October 2016, Meditech was featured on David Suzuki’s “The Nature of Things”, which will be broadcast in many countries around the world over the next several years. This achieved considerable favourable international recognition and I stress that this exposure was not solicited.

 

    • In December 2016, Dr. Gifford-Jones, a highly respected syndicated medical journalist wrote an article which was circulated in over 70 newspapers in Canada. The article commented favourably on our treatment of cerebral concussion and other neurological conditions.

 

  • In addition, many articles have been published with regard to Meditech’s Laser Technology based on our achievements in this field in a number of countries.

At this time, I enclose a prescient article written independently by Dr. Leonard Rudnick, the director of Laser Therapeutics in Tuscon, Arizona. This commentary was written in July 2007 in response to previous comments by Theralase that we originally chose to ignore as being nonsensical, much like the current five questions recently circulated. This article was written over ten years ago and is evidence of the negative trend that Theralase is intent on pursuing.






I also include an article presented by Dr. Jan Tuner, who is based in Sweden and has been highly active in the Laser Therapy sector for over 30 years. Dr. Tuner’s comments with regard to the minimal value on tissue healing of light delivered at 905 nM, the wavelength recommended by Theralase, is particularly relevant. A number of other issues are also addressed in this communication.





On a final note, I refer to a typical Theralase press release sent to me by a biotechnology analyst for my comment. The release is dated October 13, 2016. After reviewing the document, my conclusion is that a company that would release a paper of this nature has a limited understanding of research, science and integrity. Performing a study of brain cancer on a single rate, regardless of the outcome, is irrelevant at best.

Unfortunately in our society, there are no controls over this type of deceptive literature. Our conclusion is that prevarication should not be the standard for success and hopefully over time, activities of this nature should lead to the demise of the company.

Another penny stock disappearing from the Venture Exchange will certainly not be missed.







Conclusion

Some good emanates from all events, no matter what the intentions may be. This matter has provided an opportunity for Meditech to expand the educational process and clarify a number of contentious issues. The answers to the questionnaire that Theralase has posed and answered inappropriately will be fully resolved by a follow-up communication, which you should receive in April 2017.

dr kahn signature 2015-01

Fred Kahn MD, FRCS(C)

CEO, Meditech International Inc.

Laser Therapy in the Treatment of Neurological Conditions

Meditech International is a vertically integrated biotechnology company founded by Fred Kahn, MD, FRCS(C) in Toronto in 1989. Over the course of time, the company has established four treatment platforms that provide a high level of success in the treatment of a variety of medical pathologies.
The first platform includes musculoskeletal problems, sports injuries and spinal conditions.
The second introduces a revolutionary method of wound healing that is effective in a timely manner.
The third application is for the resolution of dermatological problems including psoriasis, eczema, acne, etc.

brain_sm
The most recent and exciting platform addresses the treatment of neurological conditions, focusing primarily on cerebral concussion, also known as traumatic brain encephalopathy. As we all know, cerebral concussion has become a major healthcare challenge, as the incidence of this condition increases, the result of high-level sports activities, motor vehicle accidents, military conflicts and episodes occurring throughout the course of daily activities. The negative impact on the quality of life and the stress on economic resources are incalculable. Many options are available to relieve symptoms and hopefully stimulate the healing process. Unfortunately hope, from a realistic perspective, does not produce results.
In view of the limited therapeutic options currently available, aside from being only minimally effective or scalable on an encompassing basis, there is no single application that has provided consistent, effective relief. Reputations have been built on employing nutritional and/or exercise programs, neurofeedback and prescribing an extensive number of pharmaceuticals, the majority of which compound the problem, aside from the adverse effects induced by their addictive propensities. None of these methods provide a specific, curative effect to mitigate the pathology engendered by TBI.
Symptoms generally include headaches, sleep aberrations, a complex array of cognitive and executive dysfunction, brain fog, fatigue and depression, all of which negatively impact the quality of life. Most of these symptoms may be imperceptible initially, however they generally become more evident as time progresses. This is the result of the activation of inflammatory pathways, both at the cellular and physiological level, which leads to deterioration of the neurons, axons, etc. One must be aware that neurodegenerative disorders, including the Dementias, Parkinson’s, etc. may often result from a traumatic episode at an earlier stage in the individual’s life which may have been long forgotten. It may therefore be inferred that aside from chronic pain and depression, more serious late stage degenerative conditions may also result from traumatic brain injuries sustained at an early age.
The World Health Organization has recently published statistics indicating that 6 out of every 1000 individuals have sustained some form of concussion. It is estimated that there are somewhere between 20-30 million North Americans living with TBI-related disabilities. This does not include the vast number of cases that go unreported. Efforts to improve the treatment outcomes should be a priority for all clinicians and healthcare providers involved in these endeavours.
Once a diagnosis has been established, the therapeutic options are limited. Essentially concussion patients presently are prohibited from involvement in high-risk physical activities and demanding cognitive tasks. They are encouraged to rest and pharmaceutical solutions, often widely utilized, unfortunately do not address the underlying pathologies involved.
At Meditech, over the past 10 years particularly, we have focused on the treatment of neurological conditions, primarily traumatic brain injury, as these cases present the largest cohort of neurological problems. Protocols have been developed specifically to treat both acute and chronic conditions which have been further divided into stable, labile and other categories.
It must be observed that isolated injuries to the central nervous system alone are rare. A growing body of evidence indicates that the skeletal and soft tissues of the cervical spine, along with the spinal cord, may bear the primary brunt of the trauma. Aside from the torque and whiplash forces affecting the central nervous system, structures at the atlanto-occipital junction are exceedingly vulnerable to trauma. One should also be cognizant that the injury often includes the auditory and proprioceptive mechanisms. The brain stem, located at the posterior aspect of the brain, provides continuity with the spinal cord. The cranial nerves originate in the brain stem and when a traumatic episode occurs, physiological and neurochemical changes are manifested, leading to varying degrees of neuronal impairment. Neuroprotective functions are dependent on the viability of mitochondrial metabolism, which is essential to the process of cell survival and regeneration.

duo+_smCurrent research indicates that the effects of photobiostimulation consists of the primary effect, i.e. a direct photochemical change secondary to the excitation of photoreceptors and the activation of secondary messenger cascades with subsequent modulation improving function and gene expression. The secondary effect occurs at some point subsequent to light exposure. Impaired mitochondrial oxidative metabolism is associated with neuronal degeneration and this process is reversed with the application of Light Therapy.

Mechanism of Action
Therapeutic effects are actualized via three channels. The first is the direct effect of photon particles interacting with the membranes and intracellular molecules of the cells, constituting the neurological, connective and skeletal tissues that comprise the structures undergoing therapy.
The second is the absorption of the photon or energy particles by the cerebrospinal fluid which are transmitted to the spaces surrounding the central nervous system, the ventricles and the spinal cord.
The third is the humoral effect, i.e. the absorption of photon particles by the intravascular contents and distribution to the affected tissues. The circulation of both cerebrospinal and vascular fluids play a significant role in the actualization of this process.
During 2016 at Meditech, we treated 500 cases diagnosed with cerebral concussion. The results achieved by patients that follow the prescribed therapeutic regimen in a compliant manner are well in excess of an 80% recovery rate. Protocols are continually refined and individualized based on extrapolations from our clinical experience and our extensive database. At this point, we feel that Laser Therapy is the treatment of choice for patients presenting with traumatic brain injury; moreover it offers a precise, consistent and universally effective therapeutic approach to the elimination of symptoms and the full restoration of quality of life. Modified treatment protocols have also been applied on a limited scale to Parkinson’s disease, Dementia, Autism and other neurological conditions. Results to date have exceeded our expectations and in some instances, have been dramatic.
An early and better defined recognition of the diagnosis of concussion and the institution of Laser Therapy are paramount to the resolution of this and other neurological conditions in an expeditious manner.